Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

manilatimes.net · 2026-10-01

Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestitureThe Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ('Elutia” or the 'Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE: BSX). The payment was made following an indemnity holdback period that began with the October 1, 2025 closing of the $88 million transaction. The Company believes it is funded through the first full year of the NXT-41x commercial launch and into 2029, without the need for an equity offering.

TickrTrends take: Boston Scientific's $8 million payment to Elutia positions BSX as an active investor in innovative healthcare technologies, which aligns with the company's strategic focus on expanding its portfolio beyond core devices. Given TickrTrends' current undervalued assessment of BSX, investors should monitor whether such partnership payments and technology acquisitions translate into meaningful revenue growth and margin expansion in coming years. The funding visibility Elutia now has into 2029 suggests BSX is making deliberate long-term bets in the healthcare sector, making it important to track whether these investments help justify or challenge the current valuation perspective.

Read the full story at manilatimes.net →